Geode Capital Management LLC Raises Stock Holdings in electroCore, Inc. (NASDAQ:ECOR)

Geode Capital Management LLC increased its stake in shares of electroCore, Inc. (NASDAQ:ECOR) by 10.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,485 shares of the company’s stock after purchasing an additional 5,951 shares during the quarter. Geode Capital Management LLC owned approximately 0.98% of electroCore worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its holdings in shares of electroCore by 689.1% during the third quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock worth $3,864,000 after buying an additional 467,326 shares in the last quarter. Renaissance Technologies LLC grew its stake in electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock worth $442,000 after acquiring an additional 2,270 shares during the period. Finally, HighTower Advisors LLC purchased a new stake in electroCore in the 3rd quarter worth approximately $255,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

electroCore Trading Down 2.1 %

Shares of NASDAQ:ECOR opened at $16.54 on Monday. The firm has a market cap of $108.34 million, a price-to-earnings ratio of -9.04 and a beta of 0.57. The stock’s 50-day moving average price is $13.76 and its two-hundred day moving average price is $9.32. electroCore, Inc. has a 12-month low of $5.32 and a 12-month high of $18.67.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price objective on electroCore from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.